Aromatase inhibitors and male breast cancer

Clinical and Translational Oncology

Volumn 9, Issue 3, 2007, Pages 192-194

  Arriola, Edurne ^a,b   Hui, E ^a   Dowsett, M ^a   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Aromatase inhibitor; Breast neoplasm; Letrozole; Male; Oestradiol

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN RECEPTOR; LETROZOLE; LUTEINIZING HORMONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; NITRILE; PROGESTERONE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LYMPHADENOPATHY; MALE; PHOBIA; TREATMENT RESPONSE; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PAGET NIPPLE DISEASE; SPINAL CORD TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; CYPROTERONE ACETATE; ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PHOBIC DISORDERS; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SPINAL NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 34250321005     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0034-3     Document Type: Article

References (35)

1. Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993) Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53:538-549
2. Weiss JR, Moysich KB, Swede H (2005) Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 14:20-26
3. Johnson KC, Pan S, Mao Y (2002) Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev 11:253-263
4. McClure CJ, Higgins CC (1951) Bilateral carcinoma of male breast after estrogen therapy. J Am Med Assoc 146:7-9
5. Dowsett M, Lloyd P (1990) Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. Cancer Chemother Pharmacol 27:67-71
6. Simpson E, Rubin G, Clyne C et al (1999) Local estrogen biosynthesis in males and females. Endocr Relat Cancer 6:131-137
7. Carreau S, Genissel C, Bilinska B, Levallet J (1999) Sources of oestrogen in the testis and reproductive tract of the male. Int J Androl 22: 211-223
8. Smith EP, Boyd J, Frank GR et al (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061
9. Yaffe K, Sawaya G, Lieberburg I, Grady D (1998) Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 279:688-695
10. Rayson D, Erlichman C, Suman VJ et al (1998) Molecular markers in male breast carcinoma. Cancer 83:1947-1955
11. Goss PE, Reid C, Pintilie M et al (1999) Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85:629-639
12. Farrow J, Adair F (1942) Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science 95:654-657
13. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA (1992) Carcinoma of the male breast. Ann Intern Med 117:771-777
14. Ribeiro GG (1976) The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer 33:465-467
15. Lopez M (1985) Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 55:2334-2336
16. Lopez M, Natali M, Di Lauro L et al (1993) Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 72:502-505
17. Labrie F, Dupont A, Belanger A et al (1990) Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: A case report. Clin Invest Med 13:275-278
18. Kraybill WG, Kaufman R, Kinne D (1981) Treatment of advanced male breast cancer. Cancer 47:2185-2189
19. Kantarjian H, Yap HY, Hortobagyi G et al (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143:237-240
20. Harris AL, Dowsett M, Stuart-Harris R, Smith IE (1986) Role of aminoglutethimide in male breast cancer. Br J Cancer 54:657-660
21. Aisner J, Ross DD, Wiernik PH (1979) Tamoxifen in advanced male breast cancer. Arch Intern Med 139:480-481
22. Hilliard DA, Wilbur DW, Camacho ES (1984) Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: A case report. J Surg Oncol 25:42-43
23. Patterson JS, Battersby LA, Bach BK (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64:801-804
24. Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367:595-604
25. Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of eff icacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109
26. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767
27. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802
28. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139
29. Bhatnagar AS, Muller P, Schenkel L et al (1992) Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male. J Steroid Biochem Mol Biol 41:437-443
30. Trunet PF, Mueller P, Bhatnagar AS et al (1993) Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 77:319-323
31. Mauras N, O'Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: Metabolic effects. J Clin Endocrinol Metab 85:2370-2377
32. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235-237
33. Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90:26-30
34. Italiano A, Largillier R, Marcy PY et al (2004) [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne 25:323-324
35. Phase II Study of Goserelin and Anastrozole in Men With Estrogen Receptor- or Progesterone Receptor-Positive Recurrent or Metastatic Breast Cancer. http://www.cancer.gov/clinicaltrials/SWOG-S0511